Last reviewed · How we verify
Measles Vaccine at 18 months of age
Measles Vaccine at 18 months of age is a Biologic drug developed by Medical Research Council Unit, The Gambia. It is currently in Phase 1 development. Also known as: MV.
At a glance
| Generic name | Measles Vaccine at 18 months of age |
|---|---|
| Also known as | MV |
| Sponsor | Medical Research Council Unit, The Gambia |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age (PHASE3)
- A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants (PHASE1)
- Study of Concomitant Administration of the sIPV and DTaP or MMR (PHASE4)
- Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe (PHASE3)
- Earlier Prime-BOOST Schedule to Improve MEasles Protection in High Burden Settings (PHASE2)
- Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US (PHASE3)
- A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMMA Vaccine Against Invasive Nontyphoidal Salmonella in Adults, Children, and Infants (PHASE2)
- Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Measles Vaccine at 18 months of age CI brief — competitive landscape report
- Measles Vaccine at 18 months of age updates RSS · CI watch RSS
- Medical Research Council Unit, The Gambia portfolio CI
Frequently asked questions about Measles Vaccine at 18 months of age
What is Measles Vaccine at 18 months of age?
Measles Vaccine at 18 months of age is a Biologic drug developed by Medical Research Council Unit, The Gambia.
Who makes Measles Vaccine at 18 months of age?
Measles Vaccine at 18 months of age is developed by Medical Research Council Unit, The Gambia (see full Medical Research Council Unit, The Gambia pipeline at /company/medical-research-council-unit-the-gambia).
Is Measles Vaccine at 18 months of age also known as anything else?
Measles Vaccine at 18 months of age is also known as MV.
What development phase is Measles Vaccine at 18 months of age in?
Measles Vaccine at 18 months of age is in Phase 1.
Related
- Manufacturer: Medical Research Council Unit, The Gambia — full pipeline
- Also known as: MV
- Compare: Measles Vaccine at 18 months of age vs similar drugs
- Pricing: Measles Vaccine at 18 months of age cost, discount & access